Genome-wide association studies of drug response and toxicity: An opportunity for genome medicine

Nature Reviews Drug Discovery

Volumn 16, Issue 1, 2016, Pages 1-

  Giacomini, Kathleen M ^a   Yee, Sook Wah ^a   Mushiroda, Taisei ^b   Weinshilboum, Richard M ^c   Ratain, Mark J ^d   Kubo, Michiaki ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Institute of Physical and Chemical Research   (Japan)

^c MAYO CLINIC   (United States)

^d University of Chicago   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; HLA ANTIGEN; NUDIX HYDROLASE; THIOPURINE METHYLTRANSFERASE;

AGRANULOCYTOSIS; DRUG RESPONSE; DRUG SAFETY; DRUG TOXICITY; GENE IDENTIFICATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; LETTER; PHARMACOGENOMICS; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; ADVERSE DRUG REACTION; DRUG THERAPY; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HUMAN; PHARMACOGENETICS; TRENDS;

DRUG THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PHARMACOGENETICS;

EID: 85013790260     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd.2016.234     Document Type: Letter

References (10)

1. Dolgin E. Massive schizophrenia genomics study offers new drug directions. Nat. Rev. Drug Discov. 13, 641-642 (2014).
2. Scott S. A, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin. Pharmacol. Ther. 94, 317-323 (2013).
3. Muir A. J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens. Clin. Pharmacol. Ther. 95, 141-146 (2014).
4. Martin M. A, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA B genotype and abacavir dosing: 2014 update. Clin. Pharmacol. Ther. 95, 499-500 (2014).
5. Leckband S. G, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA B genotype and carbamazepine dosing. Clin. Pharmacol. Ther. 94, 324-328 (2013).
6. Tohkin M, et al. A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J. 13, 60-69 (2013).
7. Illing P. T, Vivian J. P, Purcell A. W, Rossjohn J, & McCluskey J. Human leukocyte antigen-Associated drug hypersensitivity. Curr. Opin. Immunol. 25, 81-89 (2013).
8. Fellay J, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 464, 405-408 (2010).
9. Yang S. K, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat. Genet. 46, 1017-1020 (2014).
10. Chung W. H, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA 312, 525-534 (2014).